Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.72 USD
-0.31 (-2.06%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $14.70 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
TRDA 14.72 -0.31(-2.06%)
Will TRDA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRDA
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
Other News for TRDA
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Dyne stock tumbles 31% amid drug updates, management changes
Entrada Therapeutics Inc (TRDA) Gets a Buy from Oppenheimer
Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024